Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients - A randomized controlled double-blind and double-dummy multicentre clinical trial

Diabetes, Obesity and Metabolism

Volumn 9, Issue 4, 2007, Pages 558-565

  Li, J ^a   Tian, H ^a   Li, Q ^b   Wang, N ^c   Wu, T ^d   Liu, Y ^e   Ni, Z ^f   Yu, H ^a   Liang, J ^a   Luo, R ^b   Li, Y ^c   Huang, L ^d  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

^d The First People's Hospital of Chengdu   (China)

^e Second People's Hospital of Chengdu   (China)

^f SICHUAN UNIVERSITY   (China)

Author keywords

Nateglinide; Randomized controlled trial; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE; REPAGLINIDE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 34347379097     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00638.x     Document Type: Article

References (35)

1. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105.
2. Calles-Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 1987; 36: 1167-1172.
3. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control in type 2 diabetes, Diabetes Care 1997; 20: 1822-1826.
4. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
5. Owens DR. Repaglinide-prandial glucose regulator: A new class of oral antidiabetic drugs. Diabet Med 1998; 15: S28-S36.
6. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-744.
7. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-207.
8. Goldberg RB, Einhorn D, Lucas CP et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21: 1897-1903.
9. Jovanovic L, Dailey G III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study. J Clin Pharm 2000; 40: 49-57.
10. Jovanovic L, Hassman DR, Gooch B et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004; 63: 127-134.
11. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-484.
12. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A, the Scandinavian Repaglinide Group. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: A 1-year multicentre study. Diabet Med 2001; 18: 395-401.
13. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-207.
14. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-1665.
15. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002; 87: 4171-4176.
16. Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 1529-1533.
17. Kalbag JB, Walter YH, Nedelman JR, McLeod JF. Mealtime glucose regulation with nateglinide in healthy volunteers: Comparison with repaglinide and placebo. Diabetes Care 2001; 24: 73-77.
18. Raskin P, Klaff L, McGill J et al. Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin, Diabetes Care 2003; 26: 2063-2068.
19. Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus nateglinide monotherapy: A randomized, multicenter study. Diabetes Care 2004; 27: 1265-1270.
20. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002; 25: 1271-1276.
21. Kahn SE., Montgomery B, Howell W et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 5824-5829.
22. Khutoryansky NM, Huang WC. Imputation techniques using SAS software for incomplete data in diabetes clinical trials. Boston, MA: Pharmaceutical Industry SAS users group conference proceedings, 2001; 334-337.
23. Davies MJ, Rayman G, Grenfell A, Gray IP, Day JL, Hales CN. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med 1994; 11: 432-436.
24. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, the American Diabetes Association GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-2178.
25. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29.
26. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989; 257: E241-E246.
27. Yki-Jarvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev 1998; 14: S45-S50.
28. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia 1985; 28: 412-419.
30. Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24: 983-988.
31. Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Beta-cell function in mild type 2 diabetic patients: Effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005;28: 132-138.
32. DeFronzo RAB Lilly lecture 1987: The triumvirate: beta-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
33. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-beta: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28: 2093-2099.
34. Hu S, Wang S, Fanelli B et al. Pancreatic β-cell K ATP channel activity and membrane binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000; 293: 444-452.
35. Hansen AMK, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Repaglinide and nateglinide are differentially affected by a single-point mutation in SUR1/KIR 6.2 channels, Diabetes 2002; 51: 2789-2795.